Osteonecrosis of the jaw after a single bisphosphonate infusion in a patient with metastatic renal cancer treated with sunitinib

Onkologie

Volumn 33, Issue 6, 2010, Pages 321-323

  Bozas, George ^a   Roy, Anu ^a   Ramasamy, Vani ^a   Maraveyas, Anthony ^a  

^a HULL AND EAST YORKSHIRE HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

Adverse effects; Angiogenesis; Bisphosphonates; Osteonecrosis of the jaw; Sunitinib; VEGFR; Zoledronic acid

Indexed keywords

ALPHA INTERFERON; FLUOROURACIL; INTERLEUKIN 2; SUNITINIB; ZOLEDRONIC ACID; ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT; IMIDAZOLE DERIVATIVE; INDOLE DERIVATIVE; PYRROLE DERIVATIVE;

ADULT; ARTICLE; BONE METASTASIS; CANCER STAGING; CASE REPORT; DENTAL CARE; DRUG WITHDRAWAL; HISTOLOGY; HUMAN; HUMAN TISSUE; HYPERBARIC OXYGEN; JAW OSTEONECROSIS; KIDNEY CANCER; MALE; METASTASIS; MOUTH HYGIENE; MUCOSA INFLAMMATION; TREATMENT OUTCOME; ADJUVANT CHEMOTHERAPY; BONE NECROSIS; CARCINOMA, RENAL CELL; CHEMICALLY INDUCED; DRUG POTENTIATION; INTRAVENOUS DRUG ADMINISTRATION; JAW DISEASE; KIDNEY NEOPLASMS; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PATHOLOGY; SACRUM; SECONDARY; SPINAL NEOPLASMS;

ANTINEOPLASTIC AGENTS; BONE DENSITY CONSERVATION AGENTS; CARCINOMA, RENAL CELL; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; DIPHOSPHONATES; DRUG SYNERGISM; HUMANS; IMIDAZOLES; INDOLES; INFUSIONS, INTRAVENOUS; KIDNEY NEOPLASMS; MALE; MANDIBULAR DISEASES; MIDDLE AGED; NEOPLASM STAGING; OSTEONECROSIS; PYRROLES; SACRUM; SPINAL NEOPLASMS;

EID: 77953281764     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000313680     Document Type: Article

References (13)

1. Patyna S, Laird AD, Mendel DB, O'Farrell A M, Liang C, Guan H, Vojkovsky T, Vasile S, Wang X, Chen J, Grazzini M, Yang CY, Haznedar JO, Sukbuntherng J, Zhong WZ, Cherrington JM, Hu- Lowe D: SU14813: a novel multiple receptor tyrosine kinase inhibitor with potent antiangiogenic and antitumor activity. Mol Cancer Ther 2006;5:1774-1782.
2. Woo SB, Hellstein JW, Kalmar JR: Narrative (corrected) review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 2006;144:753-761.
3. Bamias A, Kastritis E, Bamia C, Moulopoulos LA, Melakopoulos I, Bozas G, Koutsoukou V, Gika D, Anagnostopoulos A, Papadimitriou C, Terpos E, Dimopoulos MA: Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 2005;23:8580-8587.
4. Gebara SN, Moubayed H: Risk of osteonecrosis of the jaw in cancer patients taking bisphosphonates. Am J Health Syst Pharm 2009;66:1541-1547.
5. Wessel JH, Dodson TB, Zavras AI: Zoledronate, smoking, and obesity are strong risk factors for osteonecrosis of the jaw: a case-control study. J Oral Maxillofac Surg 2008;66:625-631.
6. Brunello A, Saia G, Bedogni A, Scaglione D, Basso U: Worsening of osteonecrosis of the jaw during treatment with sunitinib in a patient with metastatic renal cell carcinoma. Bone 2009;44:173-175.
7. Christodoulou C, Pervena A, Klouvas G, Galani E, Falagas ME, Tsakalos G, Visvikis A, Nikolakopoulou A, Acholos V, Karapanagiotidis G, Batziou E, Skarlos DV: Combination of bisphosphonates and antiangiogenic factors induces osteonecrosis of the jaw more frequently than bisphosphonates alone. Oncology 2009;76:209-211.
8. Estilo CL, Fornier M, Farooki A, Carlson D, Bohle G 3rd, Huryn JM: Osteonecrosis of the jaw related to bevacizumab. J Clin Oncol 2008;26:4037-4038.
9. Greuter S, Schmid F, Ruhstaller T, Thuerlimann B: Bevacizumab-associated osteonecrosis of the jaw. Ann Oncol 2008;19:2091-2092.
10. Roelofs AJ, Thompson K, Gordon S, Rogers MJ: Molecular mechanisms of action of bisphosphonates: current status. Clin Cancer Res 2006;12: 6222s-6230s.
11. Wood J, Bonjean K, Ruetz S, Bellahcene A, Devy L, Foidart JM, Castronovo V, Green JR: Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther 2002;302:1055-1061.
12. Reid IR, Bolland MJ, Grey AB: Is bisphosphonateassociated osteonecrosis of the jaw caused by soft tissue toxicity? Bone 2007;41:318-320.
13. Schilephake H: Bone growth factors in maxillofacial skeletal reconstruction. Int J Oral Maxillofac Surg 2002;31:469-484.